Dr. Neutel: I think we've reached a crossroads in therapy with two different classes of drugs. The response rate is increased to about 75% to 80% and side the therapeutics of hypertension and it may be time to make a decision as to whether we're treating hyper-effects are lower than with moderate to large doses of single agents. Blood pressure control is achieved tension correctly.
for the angiotensin converting enzyme ( ACE ) inhibi-guess is that it can be used as a substitute in congestive heart failure. tors and the a-blockers. Dr. Moser: May I add something? In the case of ACE Dr. Neutel: Studies are being done now with some inhibitors, many of them are only effective for 8 to 12 of the newer angiotensin II antagonists in patients h; when you add a small dose of a diuretic, duration with heart failure. That data will probably be available of action is increased to 18 to 24 h. within a reasonably short time.
What about the use of ACE inhibitors in patients Dr. Neutel: That's true.
with type I and type II diabetes mellitus with nephropathy? A question for Dr. Gifford: Would you treat a patient with heart failure with a blood pressure of 90 / 60 mm Dr. Gifford: There is little doubt that their use is Hg with an ACE inhibitor? beneficial in type I diabetes mellitus with nephropathy. We do not have similar studies for type II diabetes Dr. Gifford: Very cautiously. I still think that it's mellitus. There are some data on prevention of neworthwhile trying to give a small dose of an ACE phropathy with an ACE inhibitor, but these are studinhibitor, but you have to be careful. A further de-ies in normotensives and have not been published. crease in blood pressure may adversely affect renal function.
Dr. Moser: Although the ACE inhibitors have a special effect in nephropathy, it is important to reemphaDr. Moser: It's of interest, Ray, that in the heart fail-size that in the studies that established this, more than ure trials you reviewed most of the patients were al-three-quarters of the hypertensive patients required ready on a diuretic and digoxin before the ACE was diuretics and b-blockers to lower the blood pressure added. There must not have been too many people to goal levels. In other words, several medications are who had a severe drop in their blood pressure.
necessary in the majority of hypertensive diabetics to reduce blood pressure to normal levels. in males affected at this low dose?
Dr. Gifford: I would be very cautious about using Dr. Frishman: There were actually no sexual dysfuncan ACE inhibitor for a patient in heart failure or diation complaints in the clinical trials with the low-dose betic nephropathy with a creatinine level ú 3.0 mg / b-blocker/diuretic combination. dL. Other antihypertensive drugs -loop diuretics or an a-b -blocker -are probably better choices.
Dr. Neutel: Yes, our data on side effects included sexual dysfunctions -ie, libido and potency in men -and Dr. Neutel: Dr. Moser, can we use losartan as a substitute for ACE inhibitors in patients with congestive there were no significant changes in the patients treated with the low-dose combination compared to placebo. heart failure who have developed a cough?
There have been some recent data regarding the effect on libido of women treated with higher doses of Dr. Moser: We have some data on that. In shortterm studies ( up to about 3 months duration ) , it ap-antihypertensive drugs. We tend to forget about this.
This should be tracked carefully and may not be seen pears that losartan produces beneficial effects on both the hemodynamic and neurohormonal factors in con-with lower doses.
At a recent symposium a neurologist noted that we gestive heart failure. Losartan does not cause a cough. However, it may not be as potent an antihypertensive should not pay any attention to diastolic blood pressure; most of the problems relate to systolic blood presdrug as the ACE inhibitors, probably because its action does not result in an increase in bradykinin. being developed in the 6.25 mg range ( the dosage in the bisoprolol / HCTZ combination ) . Dr. Moser: Well, you saw it in JNC V. There was an emphasis, really for the first time, on defining hypertenDr. Frishman: One of the issues with a low dose of sion not by diastolic pressures alone but also by levels an ACE inhibitor is that cough is not a dose-depenof systolic pressures. The FDA ( US Food and Drug Addent side effect. It can occur at doses of 1 mg of these ministration ) , traditionally, has used a reduction in diaagents. Side effects of many of the other drugs are stolic blood pressure compared to placebo as the critedose-dependent, so that small doses of a diuretic prorion for drug efficacy, but my guess is that in the next duce very few symptomatic or metabolic side effects. several years the FDA will redefine efficacy to include a reduction in systolic blood pressure.
Dr. Neutel: One last question -Dr. Moser, should we limit the use of calcium channel blockers in our Dr. Neutel: This is an interesting question. In the patients? data that Dr. Frishman showed comparing the ACE inhibitor enalapril with the long-acting calcium chanDr. Moser: The answer is yes for the short-acting nel blocker amlodipine and the low-dose bisoprolol / dihydropyridines; possibly yes for short-acting diltia-HCTZ combination, it suggested a decreased quality zem and verapamil. We don't know about the longof life with enalapril. The question is, don't we norterm effects of the longer-acting agents. Initial reports mally see an improvement in quality of life with ACE of excessive bleeding or an increase in malignancies inhibitors and how can you explain this?
with some of the calcium channel blockers are disturbing. We obviously need more data. We know that Dr. Frishman: That's what was seen in the study. the calcium channel blockers are effective and wellThe point to be made is that quality of life wasn't tolerated by most people, but the data on cardioproadversely affected by the low-dose diuretic / b-tection or vascular protection have been disappointblocker combination. In some of the early quality-of-ing to date. life studies a high-dose b-blocker was used and in this comparison the ACE inhibitor came out quite well. Dr. Gifford: I agree. I think that we should not be using short-acting calcium antagonists, especially Dr. Moser: Can we add the fact that there are other nifedipine. I don't like using short-acting drugs of any large-scale, double-blind, placebo-controlled stud-type because you have to give them multiple times a ies -for example, the Treatment of Mild Hyperten-day. I think if we're going to use calcium antagonists, sion Study ( TOHMS ) and the V.A. study -that also we should use the long-acting ones, whether they be showed no difference in quality-of-life improvement the dihydropyridines or the long-acting forms of veraamong different drugs. In the TOMHS study, the two pamil and diltiazem. drugs that improved quality of life more than the others were diuretics and b-blockers. This finding may Dr. Neutel: Final comments? come as a surprise to many people. Dr. Abernethy: I'd simply say that I think JNC V Dr. Neutel: Ray, is JNC VI prepared to say that low-offers excellent instruction as to the approach to treatdose combinations should be used as first-line treat-ment, even though those guidelines were formulated ment?
well before the onset of the calcium blocker controversy. It was almost as if the committee were looking Dr. Gifford: I have no idea. I kind of think that they at a crystal ball when they made their recommendamay suggest this approach as a reasonable alternative, tions about b-blockers and diuretics being used as but I don't know. preferred initial therapy. 
